Younes, Anas <br/><br/>
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Jun 2012 
 - 2183-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2011.38.0410  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Antineoplastic Agents--therapeutic use<br/>Brentuximab Vedotin<br/>Disease-Free Survival<br/>Female<br/>Hodgkin Disease--drug therapy<br/>Humans<br/>Immunoconjugates--adverse effects<br/>Male<br/>Middle Aged<br/>Recurrence<br/>Young Adult